Guangzhou Improve Medical Instruments Co., Ltd, an in-vitro diagnostics company, is scheduled to make its IPO on Shenzhen’s ChiNext exchange. The company has established a price of 25 RMB ($3.67) per share for the offering’s 18.6 million shares, making the IPO worth $68 million. Its major product is evacuated blood collection systems. Improve Medical Instruments is the only life science company among the eight companies involved in ChiNext’s second round. More details...